Replies to post #564 on Xenacare Holdings Inc.(fka XCHO)

[Ely]

Go hunt for that sheff!!!

[Bakerman_06]

sheff great DD again. I hope they understand the growing investment commmunity around their company. Keep us informed of any communication you have with them....oh and tell them not to screw up their chance of a lifetime :)

[newton2009]

$heff, Could it be this one?

Xu JM, Song ST, Feng FY, Huang FL, Yang Y, Xie GR, Xu LG, Paradiso A. Compound Keluoqu for treatment of chronic moderate to severe cancer pain: a multicenter randomized trial. ASCO Annual Meeting (2002) Abstract No. 1762

I found it under clinical trials...

http://www.cobroxin.com/research/clinical_studies.php

[stervc]

Sheff, with XCHO, The ASCO & Cobroxin...

That was an awesome piece of intel you posted with your conversation you had with one of your doctors. The American Society of Clinical Oncology (ASCO) has an outstanding piece of clinical data that all should review that confirms that Cobroxin has outperformed Ultram (tramadol hydrochloride) and ibuprofen. I think since you have been in contact with the company, I think you should call him to make sure he is aware of this as this is something that I think everyone within the field of medicine should be made aware of.

Pay particular attention to what’s in bold and underlined below:
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=16&abstractID=1762
Author(s):

Jian-Ming Xu, San-Tai Song, Feng-Yi Feng, Fu-Lin Huang, Yan Yang, Guang-Ru Xie, Li-Gong Xu, Angelo Paradiso, Beijing 307 Hospital Cancer Center, Beijing, China; Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China; Jiangsu Province Cancer Hospital, Nanjing, China; Kunming the PLA General Hospital, Kunming, China; Tianjin Cancer Hospital, Tianjin, China; Cancer Hospital, Shanghai Medical University, Shanghai, China; National Cancer Institute, Bari, Italy.


Abstract:

Background: Cobrotoxin produces intense analgesia, but the onset of response is slow, which hampered its clinical use in cancer pain. However, it is unknown whether the compound cobrotoxin (compound Keluoqu, CKLQ), a combination of cobrotoxin, tramadol hydrochloride and ibuprofen is a suitable formulation for cancer pain or not. Methods: We enrolled patients who had chronic moderate to severe cancer pain in a randomized, multicenter trial. Of the 230 eligible patients, 119 were randomized to double-blind, cross-over study, 111 entered an open-label study. In cross-over study, 59 patients were randomized to dose CKLQ, placebo, tramadol hydrochloride (group A), 61 to tramadol hydrochloride, placebo, CKLQ (group B) in order for one time. Patients in the open-label study were given the option to continue taking CKLQ for 7 days as long as they felt satisfactory in pain relief. Results: One hundred and eight patients completed the cross-over study with three units, and 11 did not. The overall relief rate of CKLQ in cross-over study was 93/111 (83.7%), higher than 75/110 (68.2%) of tramadol hydrochloride (P=0.011) and 39/111 (35.1%) of placebo (P<0.001). The mean duration of response of CKLQ was significantly long among the three agents (P<0.001). Of the 35 patients who did not respond to tramadol hydrochloride, 27(77.1%) responded to CKLQ. And of the 18 who did not respond to CKLQ, 8(55.6%) obtained satisfactory pain control to tramadol hydrochloride. In open-label study, the overall relief rate of the first-dose CKLQ was 99/111 (89.2%). The trends toward reduction in complete relief (CR), increase in partial relief (PR) and significant decrease in duration of response were observed after continuous treatment with at least 10 times of CKLQ dose. The frequency of adverse events of CKLQ was similar to that of tramadol hydrochloride. Conclusions: CKLQ might be an effective analgesic for treatment of chronic moderate to severe cancer pain as an alternative to tramadol hydrochloride. …

************************************************************

v/r
Sterling

[stervc]

With Ortho-McNeil, Johnson & Johnson and XCHO…

Ortho-McNeil works with and is a division of Johnson & Johnson (J&J) and Janssen Pharmaceuticals, Inc. …

http://www.ortho-mcneil.com/ortho-mcneil/051807_press_release.html
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD)

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., is part of Johnson & Johnson, the world's most broadly-based producer of healthcare products. J&JPRD is headquartered in Raritan, NJ, and has facilities throughout Europe and the United States. J&JPRD is leveraging drug discovery and drug development in a variety of therapeutic areas to address unmet medical needs worldwide. …

http://www.janssen.com/janssen/
Janssen Pharmaceuticals, Inc.:
http://www.ortho-mcneil.com/ortho-mcneil/
http://www.pricara.com/pricara/pages/index.jsp;jsessionid=KFTSkrhCJGWQwC6nLkYMftbjX17gG9DTQwzTlt3kYtdT6lvHYJy3!-270944810

***************************************************************************************************

Ortho-McNeil has Ultram (tramadol hydrochloride) as one of their products:
http://www.ortho-mcneil.com/ortho-mcneil/products_list.html

ULTRAM® ER (tramadol HCI) Extended-Release Tablets
www.ultram-er.com


Here is the full US Prescribing Information for Ultram (tramadol hydrochloride):
http://www.ortho-mcneil.com/ortho-mcneil/shared/pi/ultramer.pdf#zoom=100

***************************************************************************************************

This further confirms these posts below about the American Society of Clinical Oncology (ASCO) where the bottom line was…
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=16&abstractID=1762
… Conclusions: CKLQ (Cobroxin) might be an effective analgesic for treatment of chronic moderate to severe cancer pain as an alternative to tramadol hydrochloride (Ultram).
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=40520224
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=40517406

Now with this being the ”clinically proven” case that Cobroxin would logically be selected as the medicine of choice to relieve chronic moderate to severe cancer pain (and other pains) over Ultram (tramadol hydrochloride), consider what XCHO could logically conceive to be a part of making in Revenues considering since they have now received the exclusive U.S. license to market and distribute this FDA approved homeopathic treatment for chronic pain given the data indicated below:

http://www.bio-medicine.org/biology-technology-1/Circ-Pharma-Limited-Enters-Into-Development-Agreement-for-Chrono-Tramadol-With-Elan-Corporation-Plc-11895-1/

…The tramadol market in the US and Europe was worth about $1.1 billion in 2008. …

I like XCHO’s changes for growth the more I research what is happening here with this Cobroxin. I think all should familiarize themselves with the PR below which should set the stage for the next PR to come given now that the company has returned from the EMCR Conference:

http://finance.yahoo.com/news/XenaCare-Holdings-Receives-bw-1183789224.html?x=0&.v=5
XenaCare Holdings Receives Exclusive License to Market and Distribute an FDA Approved Over the Counter Treatment for Chronic Pain

v/r
Sterling